Anthera Pharmaceuticals » Science

Mihelich ED and Schevitz RW. Structure-based design of a new class of anti-inflammatory drugs: secretory phospholipase A(2) inhibitors, SPI. Biochim Biophys Acta. 1999;1441(2-3):223–28.
Snyder DW, Bach NJ, Dillard RD, Draheim SE, Carlson DG, Fox N, et. al. Pharmacology of A 001/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. J Pharmacol Exp Ther 1999;288(3):1117–24.
Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, et al. Structure-based design of the first potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat Struct Biol. 1995;2(6):458–65.
Draheim SE, Bach NJ, Dillard RD, Berry DR, Carlson DG, Chirgadze NY, et al. Indole inhibitors of human nonpancreatic secretory phospholipase A2. 3. Indole-3-glyoxamides. J Med Chem. 1996;39(26):5159–75.
Hartford M, Wiklund O, Mattsson Hultén L, Perers E, Person A, Herlitz J, et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006;108(1):55–62.
Styles LA, Schalkwijk CG, Aarsman AJ, Vichinsky EP, Lubin BH, Kuypers FA. Phospholipase A2 levels in acute chest syndrome of sickle cell disease. Blood 1996;87(6):2573–78.
Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, Day NE, et al. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2005;25(4):839–46.
Mallat Z, Simon T, Benessiano J, Ederhy S, Sebella-Arguelles C, Cohen A, et al. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol. 2007;27(5):1177–83.
Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, et al. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 1999;100(12):1280–84.
Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, et al. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol 2000;86(7):718–22.
Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 2005;46(7):1249–57.
Cancro MP, D'Cruz DP, Khamashta MA. The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J Clin Invest. 2009;119(5):1066–73.
Mease PJ. B cell-targeted therapy in autoimmune disease: rationale, mechanisms, and clinical application. J Rheumatol. 2008;35(7):1245–55.
Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med. 2005;201(2):195–200.
Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome. Ann Rheum Dis. 2003;62(2):168–71.
Fabris M, Grimaldi F, Villalta D, Picierno A, Fabro C, Bolzan M, et al BLyS and April serum levels in patients with autoimmune thyroid diseases. Autoimmun Rev. 2009 (in press).
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36(3):970–1062
Rosenson RS, Hislop C, McConnell D, Elliott M, Stasiv Y, Wang N, et al. Effects of 1-H-indole-3-glyoxamide (A 002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomized, placebo-controlled trial. Lancet 2009;373(9664):649–58.
Shaposhnik Z, Wang X, Trias J, Fraser H, Lusis AJ. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA₂ inhibitor varespladib (A-002). J Lipid Res 2009;50(4):623-9.
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994;330(23):1639–44.
Gladwin MT and Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359(21):2254–65.
Hara S, Kudo I, Chang HW, Matsuta K, Miyamoto T, Inoue K. Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis. J Biochem. 1989;105(3):395–99.
Seilhamer JJ, Pruzanski W, Vadas P, Plant S, Miller JA, Kloss J, et. al. Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J Biol Chem. 1989;264(10):5335–38.
Schröder T, Kivilaakso E, Kinnunen PK, Lempinen M. Serum phospholipase A2 in human acute pancreatitis. Scand J. Gastroenterol 1980;15(5):633–36.
Vadas P. Elevated plasma phospholipase A2 levels: correlation with the hemodynamic and pulmonary changes in gram-negative septic shock. J. Lab. Clin. Med. 1984;104(6):873–81.
Lin MK, Farewell V, Vadas P, Bookman AA, Keystone EC, Pruzanski W. Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. J. Rheumatol. 1996;23(7):1162–66.
Triggiani M, Granata F, Frattini A, and Marone G. Activation of human inflammatory cells by secreted phospholipases A2. Biochim Biophys Acta 2006;1761(11):1289–1300.
Schaloske RH and Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta. 2006;1761(11):1246–59.
Bäck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 2009;23(1):41–48.
Shah PK. Inflammation and plaque vulnerability. Cardiovasc Drugs Ther. 2009;23(1):31–40.
Boyanovsky BB and Webb NR. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther 2009;23(1):61–72.
Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009;23(1):93–101.
Hartford M, Wiklund O, Mattsson HL, Persson A, Karlsson T, Herlitz J, et al. C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes. J Intern Med 2007;262(5):526–36.
Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J. 2009 (in press).
Rana JS, Cote M, Després JP, Sandhu MS, Talmud PJ, Ninio E, et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk prospective population study. Heart. 2009;95(20):1682–87.
Fujioka D, Saito Y, Kobayashi T, Yano T, Tezuka H, Ishimoto Y, et al. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice. Circulation 2008;117(23):2977-85.
Nijmeijer R, Lagrand WK, Baidoshvili A, Lubbers YT, Hermens WT, Meijer CJ, et al. Secretory type II phospholipase A(2) binds to ischemic myocardium during myocardial infarction in humans. Cardiovasc Res. 2002;53(1):138–46.
Greco G, Balogh G, Brunelli R, Costa G, De Spirito M, Lenzi L, et al. Generation in human plasma of misfolded, aggregation-prone electronegative low density lipoprotein. Biophys J. 2009;97(2):628–35.
Hakala JK, Oorni K, Pentikainen MO, Hurt-Camejo E, Kovanen PT. Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 2001;21(6)1053–58.
Pruzanski W, Lambeau L, Lazdunsky M, Cho W, Kopilov J, and Kuksis A. Differential hydrolysis of molecular species of lipoprotein phosphatidylcholine by groups IIA, V and X secretory phospholipases A2. Biochim Biophys Acta. 2005;1736(1):38–50.
Kimura-Matsumoto M, Ishikawa Y, Komiyama K, Tsuruta T, Murakami M, Masuda S, et al. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis. 2008;196(1):81–91.
Boyanovsky B, Zack M, Forrest K, and Webb NR. The capacity of group V sPLA₂ to increase atherogenicity of ApoE-/- and LDLR-/- mouse LDL in vitro predicts its atherogenic role in vivo. Arterioscler. Thromb. Vasc. Biol. 2009;29(4):532–38.
Bostrom M, Boyanovsky B, Jordan C, Wadsworth M, Taatjes D, de Beer F, et al. Group v secretory phospholipase A2 promotes atherosclerosis. evidence from genetically altered mice. Arterioscler Thromb Vasc Biol. 2007;27(3):600–06.
de Beer FC and Webb N. Inflammation and atherosclerosis Group IIa and Group V sPLA₂ are not redundant arteriosclerosis thrombosis and vascular Biology 2006;26:1421.
Webb NR, Bostrom MA, Szilvassy SJ, van der Westhuyzen DR, Daugherty A, de Beer FC. Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2003;23(2):263–68.
Touqui L and Arbibe L. A role for phospholipase A2 in ARDS pathogenesis. Mol Med Today 1999;5(6):244–49.
Chabot S, Koumanov K, Lambeau G, Gelb MH, Balloy V, Chignard M, et al. Inhibitory effects of surfactant protein A on surfactant phospholipid hydrolysis by secreted phospholipases A2. J Immunol. 2003;171(2):995–1000.
Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, et al. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. J. Clin.Invest.1998;102(6):1152–60.
Zalewski A and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25(5):923–31.
Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523–29.
Suckling KE. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic. Expert Opin Investig Drugs. 2009;18(10):1425–30.
Serruys PW, García-García HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118(11):1172–82.
Kuypers FA and Styles LA. The role of secretory phospholipase A2 in acute chest syndrome. Cell Mol Biol (Noisy-le-grand). 2004;50(1):87–94.
Styles LA, Aarsman AJ, Vichinsky EP, Kuypers FA. Secretory phospholipase A(2) predicts impending acute chest syndrome in sickle cell disease. Blood 2000;96(9):3276–78.
Kim DK, Fukuda T, Thompson BT, Cockrill B, Hales C, Bonventre JV. Bronchoalveolar lavage fluid phospholipase A2 activities are increased in human adult respiratory distress syndrome. Am J Physiol. 1995;269:L109–18.
Ackerman SJ, Kwatia MA, Doyle CB, and Enhorning G. Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest. 2003;123(3 suppl):355S.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. JAMA 2001;285:1711–18.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495–504.
Wiviott SD, de Lemos JA, Cannon CP, Blazing M, Murphy SA, McCabe CH, et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid lowering trials A to Z and PROVE-IT TIMI 22. Circulation 2006;113(11):1406–14.
Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352(1):20–28.
Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363–69.
Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease Circulation 2001;103:1813–18.
Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145(1):21–29.
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001;344(26):1959–65.
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortlaity in unstable coronary artery disease A for the FRISC study group. N Engl J Med 2000;343(16):1139–47.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195–207.
Ridker PM, Rifai N, Rose L, Buring JE, and Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 2002;347(20):1557–65.
Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future coronary heart disease in initially healthy middle-aged men: results from the MONICA Augsberg Cohort study, 1984 to 1992. Circulation 1999;99:237–42.
Albert CM, Ma J, Rifai N, Stampfer MJ, and Ridker PM. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death Circulation. 2002;105(22):2595–99.
Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J 2000;21:1584–90.
Ridker PM, Glynn RJ, and Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97(20):2007–11.
Ridker PM, Buring JE, Cook NR, and Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107(3):391–97.
Blake GJ, Ridker PM, Kuntz KM. Projected life-expectancy gains with statin therapy for individuals with elevated C-reactive protein levels. J Am Coll Cardiol 2002;40(1):49–55.
Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid a protein in sever unstable angina. N Engl J Med 1994;331(7):417–24.
Morrow DA, Rifai N, Antman EM, Weiner DL, McCabe CH, Cannon CP, et al. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. thrombolysis in myocardial infarction. J Am Coll Cardiol 1998;31:1460–65.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135–43.
Mulvihill NT and Foley JB. Inflammation in acute coronary syndromes. Heart. 2002;87(3):201–04.
Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, and Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000–06.
Pasceri V, Willerson JT, Yeh ET. Pro-inflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102(18):2165–68.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, and Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–79.
Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses BMJ 2000;321(7255):199–204.
Sakkinen P, Abbott RD, Curb JD, Rodriguez BL, Yano K, and Tracy RP. C-reactive protein and myocardial infarction. J Clin Epidemiol 2002;55(5):445–51.
Bhatt DL and Topol EJ. Need to test the arterial inflammation hypothesis Circulation 2002;106(1):136–40.
van der Wal AC, Becker AE, van der Loos CM, and Das PK. Site of intimal rupture or erosion of thrombosed atherosclerotic plaques is charcterised by an inflammatory process irrespective of the dominant plaque morphology Circulation. 1994;89(1):36–44.
Kaartinen M, Penttilä A, and Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the prediliction site of atheromatous rupture. Circulation 1994;90(4):1669–78.
Nijmeijer R, Meuwissen M, Krijnen PAJ, van der Wal A, Piek JJ, Visser CA, et al. Secretory phospholipase A2 in culprit coronary lesions associated with myocardial infarction. Eur J Clin Invest. 2008;38(4):205–10.
Koenig W and Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007;27(1):15–26.
Hartford M, Wiklund O, Mattsson-Hulten L, Perers E, Person A, Herlitz J, et. al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 2006;108(1):55–62.
Porela P, Pulkki K, Voipio-Pulkki LM, Pettersson K, Leppanen V, Nevalainen TJ. Level of circulating phospholipase A2 in prediction of the prognosis of patients with suspected myocardial infarction. Basic Res Cardiol 2000;95(5):413–17.
Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, et al. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict instability. Circulation 1999;99:855–60.
Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AT, Ginnetti F, et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first two days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999;99:2079–84.
Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitivity c-reactive protein levels. Circulation 2001;103:1933–35.
Plenge JK, Hernandez TL, Weil KM, Poirier P, Grunwald GK, Marcovina SM, et al. Simvastatin lowers c-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447–52.
Musial J, Undas A, Gajewski P, Jankowski M, Sydor W, and Szczeklik A. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolaemia. Int J Cardiol 2001;77:247–53.
Liao JK. Effect of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low density lipoprotein cholesterol. Am J Cardiol 2005;96(5A):24F–33F.
Nissen SE, Tuzcu EM, Sheonhagen P, Crowe T, Sasiela WJ, Tsai J, et al for the REVERSAL investigators. Statin therapy, LDL cholesterol, c-reactive protein, and coronary artery disease. N Engl J Med 2005;332:29–38.
Albert MA, Danielson E, Rifai N for the PRINCE Investigators. Effect of statin therapy on c-reactive protein levels: the pravastatin/inflammation CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64–70.
Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, et al. High dose atorvastatin enhances the decline in inflammation markers in patients with acute coronary syndrome in the MIRACL study. Circulation 2003;108(13):1560–66.
Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, et al. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice. J Cardiovasc Pharmacol 2009;53:60–65.
Bargoma EM, Mitsuyoshi JK, Larkin SK, Styles LA, Kuypers FA, Test ST. Serum c-reactive protein parallels secretory phospholipase A2 in sickle cell disease patients with vasoocclusive crisis or acute chest syndrome. Blood. 2005;105(8):3384–85.
Field JJ, Krings J, White NL, Yan Y, Blinder MA, Strunk RC, et al. Urinary cysteinyl leukotriene E(4) is associated with increased risk for pain and acute chest syndrome in adults with sickle cell disease. Am. J. Hematol. 2009;84:158–160.
Castro O, Brambilla DJ, Thorington B, Reindorf CA, Scott RB, Gillette P, et. al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The cooperative study of sickle cell disease. Blood 1994;84(2):643–49.
Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, et. al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National acute chest syndrome study group. N Eng J Med 2000;342(25):1855–65.
Hankins J and Aygun B. Pharmacotherapy in sickle cell disease--state of the art and future prospects. Br J Haematol. 2009;145(3):296–308.
Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289(13):1645–51.
Mackay F and Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465–75.
Martin F and Chan AC. B cell immunology in disease: evolving concepts from the clinics. Annu Rev Immunol. 2006;24:467–96.
Fairweather D, Frisancho-Kiss S, Rose NR. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol. 2008;173(3):600–09.
Kalled SL. The role of BAFF in immune function and implications for autoimmunity. Immunol Rev. 2005;204:43–54.
Thaunat O, Natacha P, Gautreau C, Lechaton S, Fremeaux-Bacchi V, Dieu-Nosjean M, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation. 2008;85:1648-53.
Sarantopoulos S, Stevenson K, Kim H, Cutler C, Bhuiya N, Schowalter M, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009;113:3865-74.
Levesque M. Translational mini-review series on B cell-directed therapies: recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol. 2009;157:198-208.
Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008; 35:1256-64.
Eisenberg R and Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006; 2(1):20-27.

sPLA₂
BLYS/BAFF